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Abstract The expression of MyoD can activate muscle specific 
genes and myogenic differentiation in many cell types. The 
hypothesis that the DNA binding specificity of MyoD is 
responsible for its biological specificity was tested. Homodimers 
of MyoD bind to E-box containing DNA with high affinity, but 
do not form stable and well defined complexes with heterologous 
DNA sequences. The physiologically active heterodimer of 
MyoD and E12 binds an oligonucleotide containing an E-box 
sequence with an affinity only two orders of magnitude higher 
than a completely unrelated DNA sequence, stressing the 
importance of cooperative interactions with other proteins of 
the transcriptional machinery for specific gene activation. 
Key words: Transcription factor; Protein-DNA interaction; 
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I. Introduction 
MyoD (Fig. IA) is a member of a family of transcription 
factors involved in the cellular differentiation of the myoblasts 
of the skeletal musculature [1]. Experiments in transgenic mice 
have shown that MyoD is responsible for myoblast determi- 
nation [2,3]. In tissue culture the expression of the MyoD gene 
is capable of activating previously silent muscle specific genes 
in myoblasts as well as in many other cell types [4-6]. Surpris- 
ingly, a domain of MyoD called the basic helix-loop-helix 
(BHLH) domain, comprising only 68 amino acid residues, 
was sufficient for stable myogenic onversion of C3H 10Tl/2 
fibroblasts uggesting that MyoD acts as a 'master egulator' 
of muscular differentiation [7]. The X-ray structure analysis of 
cocrystals of the MyoD BHLH domain and a double stranded 
oligonucleotide indicated that the HLH domain mediates di- 
merization of two MyoD monomers, while the DNA is con- 
tacted mainly through residues of the basic region [8]. In vivo 
the functionally active species of MyoD is an heterodimer 
with either one of the ubiquitously expressed E2A gene prod- 
ucts, El2 or E47 [9]. The activity of the MyoD/E12(47) het- 
erodimer as a transcriptional ctivator depends on the pres- 
ence of a DNA sequence containing the core motif CANNTG 
(E-box) [10]. 
Since an E-box occurs on average every 256 bp in the 
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genome the exquisite physiological specificity of MyoD ap- 
pears paradoxical. It has been suggested that MyoD displays 
different affinities for DNA sequences containing different E- 
boxes. In fact, CASTing [11] and SAAB [12] experiments re- 
vealed preferential binding to DNA containing the sequence 
CAGCTG, and a preference for the nucleotide sequence GA, 
flanking the E-box on the 5' side. In addition, the sequence 
preferences of the MyoD homodimer and of the heterodimer 
with E47 were different [12] suggesting a second pathway for 
the generation of sequence specificity. A mechanism in which 
the specificity of muscular gene expression is solely controlled 
by the specificity of DNA binding of MyoD, can be functional 
in vivo only if the affinities of MyoD for individual E-box 
sequences differ significantly. 
We have, therefore, measured the apparent dissociation 
constants of the complexes of MyoD homodimers and of 
MyoD/E12 heterodimers with oligonucleotides of different se- 
quences. The apparent dissociation constant (KD) of the func- 
tionally active heterodimer of MyoD and El2 is only two 
orders of magnitude smaller for the complex with E-box con- 
taining DNA sequences than with unrelated DNA. The differ- 
ences between the affinities for different E-box sequences are 
even smaller, implying that the specificity of transcriptional 
activation of muscle specific genes by MyoD cannot be ex- 
plained by a mechanism which relies solely on the specificity 
of DNA binding of MyoD. However, most likely it will be 
achieved through cooperative interaction with other factors of 
the transcriptional machinery, such as the myocyte specific 
enhancer factor, MEF-2C [13]. 
2. Materials and methods 
2.1. Expression of MyoD 
A fragment of the murine MyoD cDNA (Fig. 1A), coding for the 
BHLH domain from Ala l°s to Asp 166 and with Cys 133 replaced by Ser 
(this mutation does not noticeably affect he properties of MyoD [8]) 
was expressed from the T7 promoter [14] in BL21(DE3) cells essen- 
tially as described [15]. 
2.2. Protein purification 
MyoD protein was purified as described for the purification of the 
BHLH domain of MASH-1 [15]. Protein concentrations were deter- 
mined by measuring the UV absorptions at215 and 220 nm [16]. The 
protein was homogeneous by SDS-gel electrophoresis and by ion ex- 
change HPLC. Laser desorption time of flight mass spectrometry 
showed sample homogeneity and correct molecular mass. The se- 
quence of the first seven amino-terminal residues was confirmed by 
automated Edman degradation. 
Full-length El2 from rat was expressed and purified as previously 
described [15]. 
2.3. Oligonucleotides 
Oligonucleotides were purchased from Microsynth. DNA sequences 
are shown in Fig. lB. Single stranded oligonucleotides were labelled 
with [32p]ATP (Amersham) in the presence of T4 polynucleotide ki- 
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nase (New England Biolabs) and complementary strands annealed by 
heat denaturation followed by slow cooling to room temperature. 
2.4. Electrophoretic mobility shift assays 
Aliquots from stock solutions of the proteins were heated to 45°C 
for 5-10 min in the presence of 10 mM DTT and then allowed to cool 
to room temperature over a period of 2 h prior to every assay. For 
experiments with heterodimers equimolar amounts of MyoD and El2 
were used. Stock solutions were then serially diluted and incubated in 
50 mM Tris (pH 7.9), 6 mM MgC12, 40 mM ammonium sulfate, 0.2 
mM EDTA, 1 mM DTT, and 4% glycerol for 15 min at ambient 
temperature prior to mixing with the labelled oligonucleotide. These 
solutions were incubated for 15 min at room temperature and were 
applied to 4% polyacrylamide g ls in 0.9 × TAE (pH 7.9), dried, and 
exposed to Kodak X-OMAT S film at -70°C. Quantitative data were 
obtained with a Direct Imager (Packard). 
2.5. Data analysis 
Apparent dissociation constants for the DNA complexes of MyoD 
were determined as previously described [15]. For the heterodimer 
between MyoD and El2 the apparent dissociation constant was cal- 
culated according to the following formula: KD(ME)={([E2D] × [M])/ 
([MED] X [E])} X KD(E2). 
KD(ME) and KD(E2) are the apparent dissociation constants for the 
DNA complexes of MyoD/E12 hetero- and El2 homodimer, espec- 
tively. For KD(E2) a value of 1.9X 10 -16 M 2 was used [15]. [E2D], 
[M2D], and [MED] can be measured in the titration experiments, 
while both [M]:[M]tot-2[M2D]-[MED] and [E]=[E]tot-2[E~D] - 
[MED] can be calculated from measured values. 
2.6. CD spectroscopy 
Spectra were measured on a Jasco J600 circular dichroism spectro- 
photometer atambient emperature. The concentration of MyoD was 
1 gM in 5 mM Tris (pH 7.0), 0.25 mM DTT. 
3. Results and discussion 
Results from SAAB and CASTing experiments have been 
interpreted to show that MyoD could distinguish its DNA 
target sequences from similar sequences in other regulatory 
DNA elements through subtle differences of the interactions 
of the protein with specific and non-specific DNA sequences 
[11,12]. In addition, based on the strong evidence that the 
heterodimer between MyoD and the ubiquitous E12/47 pro- 
tein is the functionally active species in vivo, it has been pro- 
posed that heterodimerization might provide an additional 
source of DNA binding specificity [9]. 
In order to determine the DNA binding specificity of 
MyoD, both as a homodimer and as a heterodimer with the 
E l2  protein, we have produced in E. coli and purified to 
apparent homogeneity the BHLH domain of MyoD (Fig. 
1A) and characterized its DNA binding properties by electro- 
phoretic mobility shift assays. An oligonucleotide (MCK-S) 
comprising 17 bp of the IgH enhancer like element of the 
muscle specific creatine kinase enhancer which contains the 
central E-box sequence CAGGTG,  was used as a DNA probe 
(Fig. 1B) [17]. Both MyoD and E l2  homodimers as well as 
MyoD/E12 heterodimers formed stable complexes with MCK-  
S (Fig. 2). Mixing equimolar amounts of MyoD and E l2  gave 
rise to two bands corresponding to the DNA complexes of the 
E l2  homodimer and the heterodimer of E l2  and MyoD in- 
dicating that they both had similar affinities for MCK-S, while 
the affinity of the MyoD homodimer for MCK-S was signifi- 
cantly lower (Fig. 2). 
Circular dichroism spectroscopy showed that the BHLH 
domain of MyoD was largely unfolded at a concentration 
of 1 gM (Fig. 3). Addition of the MCK oligonucleotide to 
this solution induced a change in the CD spectrum indicative 
of the transition of MyoD to a largely a-helical conformation 
upon DNA binding. This transition could be saturated, in 
that the addition of DNA in excess of a MyoD to DNA-  
duplex ratio of 2 did not lead to a further change of the 
CD spectrum, demonstrating that one protein dimer bound 
to one DNA duplex. 
In titration experiments, the apparent dissociation constants 
(KD) of the DNA complexes of MyoD with several different 
oligonucleotides were determined (Table 1). Increasing 
amounts of protein were added to a constant amount of 
DNA (Fig. 4A). The concentration of protein [P]1/2, at which 
half of the protein binding sites were filled, was determined 
from graphs describing the dependence of O, the fraction of 
DNA bound to protein, on the concentration of the unbound 
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Fig. 1. (A) Sequence alignment of the BHLH domains of murine MyoD* (Cys la5 of the wild type sequence was replaced with Ser) [8] and El2 
and E47 from rat [28]. The numbering system of full-length MyoD is indicated. (B) Sequences of the oligonucleotides u ed in the EMSAs. The 
E-box and the nucleotide flanking the E-box on the 5' side are in bold print. 
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Fig. 2. Binding of MyoD (lane 2) and El2 (lane 3) to the MCK-S 
oligonucleotide, and of a mixture of equimolar amounts of MyoD 
and El2 to MCK-S (lane 4) and SP-1 oligonucleotide (lane 5), re- 
spectively. Lane 1: MCK-S in the absence of protein. 
protein (Fig. 4B) [18]. Since the stoichiometry of the complex 
between MyoD and DNA is 2:1 (see above) [19], the dissocia- 
tion constant was calculated as KD=([P]a/2) 2. The KD for the 
complex of MyoD with MCK-S was found to be 2.2 x 10 -14 
M 2, in good agreement with a previous report [19]. MyoD 
homodimer bound E-box containing DNA sequences about 
two orders of magnitude weaker than E12 homodimer [15] 
(Table 1). 
Titration experiments with DNA sequences not containing 
E-box sequences (Fig. 1B) were performed in order to deter- 
mine the DNA binding specificity of the BHLH domain of 
MyoD. Unlike the oligonucleotides containing E-box se- 
quences, these oligonucleotides did not form well defined 
complexes with MyoD. However, the great number of ob- 
served bands as well as the decrease of the concentration of 
free DNA with increasing amounts of MyoD (Fig. 4C) indi- 
cated the formation of many MyoD-DNA complexes, all with 
molecular weights smaller than that of the complex of MyoD 
with E-box containing DNA sequences. The MyoD concen- 
tration giving rise to half-maximal DNA binding was more 
than 10 times higher for heterologous oligonucleotides than 
for DNA sequences containing an E-box (Fig. 4C). 
MyoD folding, homodimerization, and binding of the 
MyoD dimer to E-box containing DNA sequences are ener- 
getically coupled processes (Fig. 3). At high concentration, 
MyoD forms dimers even in the absence of DNA (KD "~ 31 
p.M) [20]. However, at the submicromolar concentrations 
where half-maximal DNA binding occurs (Fig. 4B and Table 
1), MyoD dimers are dissociated and predominantly exist as 
unfolded monomers. It is consistent with our data to hypothe- 
size that this DNA induced dimerization is a DNA sequence 
specific process only induced by DNA containing an E-box 
sequence. Heterologous DNA sequences appear not to cause 
dimerization under the conditions of the EMSA. However, 
due to the great number of positive charges in the basic region 
81 
of MyoD, these heterologous DNA sequences can, neverthe- 
less, interact with aggregating protein monomers of poorly 
defined structures, giving rise to a great number of different 
retarded bands. 
While this interpretation of the specificity of DNA binding 
of MyoD homodimer might be interesting from a structural 
point of view, it is not relevant o the function of MyoD in 
vivo, because the physiologically active species is the hetero- 
dimer of MyoD and El2 [9]. We therefore investigated the 
DNA binding properties of the heterodimer. The apparent 
dissociation constants with several oligonucleotides revealed 
that MyoD/E12 heterodimers bound E-box containing DNA 
sequences, with an affinity approximately two orders of mag- 
nitude higher than MyoD homodimers (Fig. 2 and Table 1). 
However, when compared to the homodimer of El2 [15], the 
apparent dissociation constant was reduced by only three- 
fold. 
For El2 homodimers, the biggest difference in KD for the 
complexes with E-box containing sequences was observed 
when the nucleotide flanking the E-box on the 5' side was 
changed from a purine to a pyrimidine base [15]. The same 
observation was made for the heterodimer of MyoD and El2 
where the affinity was reduced by one order of magnitude 
when the guanine on the 5' side of the E-box of MCK-S 
was replaced by a cytosine (Table 1). Changing the central 
two base pairs of the E-box had significantly smaller effects 
(data not shown). 
The crystal structure analysis of MyoD revealed a water 
mediated contact between the carboxylate of Glu 11s and N 7 
of the adenine flanking the E-box on the 5' side [8]. This 
stabilizing interaction will be lost if adenine is replaced by a 
pyrimidine base. Experiments in transgenic mice have shown 
that for the myogenin promoter, the proximal E-box, in which 
a guanine flanks the E-box on the 5' side, can be replaced 
with an E-box sequence containing a thymine in the 5' posi- 
tion without changing the expression pattern of the myogenin 
gene during embryogenesis [21], thereby providing evidence 
that a difference in Ko of only one order of magnitude is 
insignificant in vivo, at least in the context of the myogenin 
promoter. 
The DNA binding specificities of the MyoD/E12 heterodi- 
mer and the El2 homodimer were very similar (Table 1). In 
both cases, the protein concentration required for half max- 
• -t 5 
,q f )  
-15  
200 360 
[nat] 
Fig. 3. CD spectra of the BHLH domain of MyoD in the presence 
of increasing amounts of MCK-S. (a) 0.4 p.M MCK-S (no MyoD 
present); (b-f) [MyoD]= 1 ~tM with 0, 0.1, 0.3, 0.5, 0.8 IxM MCK- 
S. Spectra b-f are difference spectra between the CD spectrum of 
the MyoD-MCK-S-complex and MCK-S in the absence of MyoD. 
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Table 1 
Apparent dissociation constants (Kr), M 2) for the DNA complexes of the homodimers of MyoD and El2 [Meierhans], and for the heterodimers 
of El2 with MyoD and MASH-1 [Meierhans] 
MyoD El2 MyoD/E12 MASH-1 MASH-lIE12 
MCK-S 2.2( -+ 0.5)E14 1.9( + 0.9)E 16 5.7( + 1.0)El7 1.4( _+ 0.1)El4 7.2( + 1.2)El 7 
E-Box 5'C 2.1( -+ 0.1)El4 2.0( -+ 0.4)E 15 1.2( _+ 0.5)El 5 3.9( _+ 0.4)E 14 4.9( + 1.3)E16 
MCK-MUT nc 3.6( + 1.3)E14 2.0( _+ 1.3)E14 1.4( + 0.4)El 3 1.3( + 0.4)El 5 
SP1-WT nc 2.4( _+ 0.8)E14 6.2( _+ 0.8)El 5 7.7( _+ 1.2)E14 1.8( + 0.4)El 5 
NOE-BOX nc 4.4( + 0.9)E14 1.9( + 1.1)El4 1.4( _+ 0.3)E13 1.2(+ 0.3)El 5 
nc: MyoD homodimers do not form stable 2:1 complexes with these oligonucleotides. 
imal DNA binding was only 10 times smaller for binding to 
E-box containing DNA sequences than to heterologous DNA. 
The heterodimers of MyoD and El2 display, therefore, only 
marginally higher DNA binding specificity than the heterodi- 
mers of E l2 with the nerve cell specific protein, MASH-1 
(Table 1) [15]. Low DNA sequence specificity seems to be a 
general feature of the BHLH family of transcription factors. 
It is noteworthy in this context that removing the leucine 
zipper from the human transcriptional ctivator USF, which 
uses a BHLH-leucine zipper motif for dimerization and se- 
quence specific DNA recognition, leaves a DNA binding re- 
gion which also shows only marginal specificity of DNA bind- 
ing [22]. 
In the light of the crystal structure of the DNA complex of 
MyoD homodimer [8], the modest DNA binding specificity 
displayed by BHLH proteins can be rationalized. Most amino 
acid residues involved in the interaction between MyoD and 
DNA make sequence independent contacts to the phosphate 
A MCK-S 
B . C 
. . . .  • "' I 1 .o  
t t o .6  M~L~-S .~. O.6 
eo 
-i0 -9 -8 -7 -6 -5 -4 -i0 -9 -8 -7 -6 -5 -4 
log [MyoD] log [MyoD] 
Fig. 4. (A) Autoradiogram of titration of 9.66 nM MCK-S with 14.4, 21.6, 36, 50.5, 72.1, 144.2, 216.2, 360.4, 504.5, and 720.7 nM MyoD. (B) 
Fraction ~ of bound MCK-S in the MyoD-MCK-S complex vs. the concentration f free MyoD. (C) Fraction ~'  of free DNA vs. the concen- 
tration of the free protein. 
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backbone. Only two residues of each MyoD monomer make 
specific contacts to three bases of one DNA half-site. This is 
in sharp contrast o the large number of specific interactions 
in the DNA complexes of DNA-methyltransferases which rely 
on very high sequence specificity for proper function [23,24]. 
It is clear from our results that sequence specific DNA 
binding of MyoD cannot explain (at least not as the sole 
mechanism) the extraordinary specificity of transcriptional c- 
tivation during muscular differentiation, which must be ob- 
tained in large part through cooperative interactions with 
other transcription factors, such as MEF-2C [13]. Recently 
published results from transfection experiments with 10T1/2 
fibroblasts also indicated that MEF-2C acts as a coregulator 
to potentiate the myogenic activity of the MyoD/E12 hetero- 
dimer through direct interaction between the individual DNA 
binding domains [25]. 
Both the affinity and the specificity of DNA binding of the 
MyoD/E12 heterodimer are comparable to that of the El2 
homodimer and the question arises why El2 does not induce 
muscular differentiation i the absence of MyoD. The repla- 
cement of only two amino acid residues in the basic region 
and of one residue in the amino terminal region of helix 1 of 
El2 with the corresponding amino acids from MyoD are en- 
ough for the acquisition of myogenic specificity of El2 [26]. 
The two residues of the basic region are located on the inter- 
face between the DNA duplex and the protein, suggesting that 
they might be involved in controlling the specificity of DNA 
binding, while the third residue required for myogenic onver- 
sion protrudes into the solvent [8,27]. Our data show that 
these three amino acid changes do not significantly alter the 
DNA binding specificity of El2. Rather, these three residues 
control the potential of El2 and MyoD to interact with other 
proteins involved in the transcriptional regulation of muscle 
specific genes. In such a mechanism the basic region is respon- 
sible for sequestering the BHLH proteins to DNA, while se- 
quence specificity and, consequently, the specificity of tran- 
scriptional activation is mainly achieved through cooperative 
interactions. 
Acknowledgements: This work was supported by an ETH grant 
(R.K.A.). We thank Dr. Carl O. Pabo for providing the MyoD plas- 
mid; David J. Anderson for providing the cDNA of El2; Lesley A. 
Tannahill and Martin Sieber for critical reading of the manuscript and 
for helpful discussions. 
References 
[1] Sassoon, D., Lyons, G., Wright, W.E., Lin, V., Lassar, A., Wein- 
traub, H. and Buckingham, M. (1989) Nature 341, 303-307. 
[2] Hasty, P., Bradley, A., Morris, J.H., Edmondson, D.G., Venuti, 
J.M., Olson, E.N. and Klein, W.H. (1993) Nature 364, 501-506. 
[3] Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., 
Nanoka, I. and Nabeshima, Y. (1993) Nature 364, 532-535. 
[4] Buckingham (1992) Trends Genet. 8, 144-149. 
[5] Olson, E. (1990) Genes Dev. 4, 1454-1461. 
[6] Weintraub, H., Davis, R., Tapscott, S., Thayer, M, Krause, M., 
Benezra, R., Blackwell, T.K., Turner, D., Rupp, R., Hollenberg, 
S., Zhuang, Y. and Lassar, A. (1991) Science 251, 761-766. 
[7] Tapscott, S.J., Davis, R.L., Thayer, M.J., Cheng, P.-F., Wein- 
traub, H. and Lassar, A.B. (1988) Science 242, 405-411. 
[8] Ma, P.C.M., Rould, M.A., Weintraub, H. and Pabo, C.O. (1994) 
Cell 77, 451- 459. 
[9] Lassar, A.B., Davis, R.L., Wright, W.E., Kadesch, T., Murre, C., 
Voronona, A., Baltimore, D. and Weintraub, H. (1991) Cell 66, 
305-315. 
[10] Lassar, A.B., Buskin, J.N., Lockshon, D., Davis, R.L., Apone, 
S., Hauschka, S.D. and Weintraub, H. (1989) Cell 58, 823-831. 
[11] Wright, W.E., Binder, M. and Funk, W. (1991) Mol. Cell. Biol. 
11, 4104-4110. 
[12] Blackwell, T.K. and Weintraub, H. (1990) Science 250, 1104- 
1110. 
[13] Olson, E.N., Perry, M. and Schultz, R.A. (1995) Dev. Biol. 172, 
2-14. 
[14] Studier, F.W. (1991) J. Mol. Biol. 219, 37-44. 
[15] Meierhans, D., el Ariss, C., Neuenschwander, M., Sieber, M., 
Stackhouse, J.F. and Allemann, R.K. (1995) Biochemistry 34, 
11026-11036. 
[16] Wetlaufer, D.R. (1962) Adv. Protein Chem. 17, 303-390. 
[17] Buskin, J.N. and Hauschka, S.D. (1989) Mol. Cell. Biol 9, 2627- 
2640. 
[18] Clore, G.M., Gronenborn, A.M. and Davies, R.W. (1982) J. 
Mol. Biol. 155, 447-466. 
[19] Sun, X.-H. and Baltimore, D. (1991) Cell 64, 459-470. 
[20] Fairman, R., Beran-Steed, R.K., Anthony-Cahill, S.J., Lear, 
J.D., Stafford III, W.F., DeGardo, W.F., Benfield, P.A. and 
Brenner, S.L. (1993) Proc. Natl. Acad. Sci USA 90, 10429-10433. 
[21] Yee, S.-P. and Rigby, P.W.J. (1993) Genes Dev. 7, 1277-1289. 
[22] Sha, M., Ferrr-D'Amarr, A.R., Burley, S.K. and Goss, D.J. 
(1995) J. Biol. Chem. 270, 19325 19329. 
[23] Reinisch, K.M., Chen, L., Verdine, G.L. and Lipscomb, W.N. 
(1995) Cell 82, 143-153. 
[24] Klimasaukas, S., Kumar, S., Roberts, R.J. and Cheng, X. (1994) 
Cell 76, 357-369. 
[25] Molkentin, J.D., Black, B.L., Martin, J.F. and Olson, E.N (1995) 
Cell 83, 1125-1136. 
[26] Davis, R.L. and Weintraub, H. (1992) Science 256, 1027-1030. 
[27] Ellenberger, T., Fass, D., Arnaud, M. and Harrison, S.C. (1994) 
Genes Dev. 8, 970-980. 
[28] German, M.S., Blanar, M.A., Nelson, C., Moss, L.G. and Rut- 
ter, W.J. (1991) Mol. Endocrinol. 5, 
